Key result
Lipoprotein apheresis reduces CRP levels without significantly altering IL-6, TNF-α, or hs-CRP.
Why the study?
Does lipoprotein apheresis reduce circulating inflammatory markers in patients with dyslipidemia unresponsive to conventional lipid-lowering strategies?
Meta-Analysis
Does lipoprotein apheresis reduce circulating inflammatory markers in patients with dyslipidemia unresponsive to conventional lipid-lowering strategies?
Answers are grounded in this paper and cite their sources.
Lipoprotein apheresis provides a modest anti-inflammatory benefit by reducing CRP levels in patients with refractory dyslipidemia, though it does not significantly affect other inflammatory markers.
Lipoprotein apheresis is a well-established therapy for patients with dyslipidemia unresponsive to conventional lipid-lowering strategies. However, its impact on systemic inflammation remains uncertain. This systematic review and meta-analysis evaluated the effect of apheresis on circulating inflammatory markers, including C-reactive protein (CRP), high-sensitivity CRP (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). Following PRISMA guidelines, a systematic search of PubMed, Scopus, and ISI Web of Science was conducted up to June 2025. Studies reporting pre- and post-apheresis values for inflammatory markers were included. Standardized mean differences (SMD) and 95% confidence intervals (CI) were calculated. Thirteen publications met inclusion criteria. Meta-analysis demonstrated that apheresis significantly reduced CRP levels (SMD = -0.31; 95% CI: -0.44 to -0.18; p < 0.001), particularly in long-term interventions. No significant changes were observed for IL-6, TNF-α, or hs-CRP. In conclusion, apheresis significantly reduces CRP levels, especially with long-term treatment, suggesting a modest anti-inflammatory benefit. However, its effects on other markers remain unclear. Larger and high-quality trials are warranted.
No takes yet. Share an insight, caveat, or question.
Hatami et al. (2025) conducted a meta-analysis in dyslipidemia unresponsive to conventional lipid-lowering strategies. Lipoprotein apheresis vs. pre-apheresis values was evaluated on CRP levels (SMD -0.31, 95% CI -0.44 to -0.18, p=< 0.001). Lipoprotein apheresis reduced CRP levels, particularly with long-term treatment, but had no significant effect on IL-6, TNF-α, or hs-CRP.
Synapse has enriched 10 related papers. Consider them for comparative context: